Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - topotecan - uterine cervical neoplasms; small cell lung carcinoma - other antineoplastic agents - topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate. topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.,

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - fesoterodine fumarate - urinary bladder, overactive - urologicals - treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibacterials for systemic use, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.,

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics for systemic use - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidosis - other nervous system drugs - vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials for systemic use, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibacterials for systemic use, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.,

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - zoledronic acid monohydrate - hypercalcemia - drugs for treatment of bone diseases - 4 mg / 5 ml and 4 mg / 100 ml:prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).5 mg / 100 ml:treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.treatment of paget's disease of the bone in adults.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory cd22-positive b cell precursor acute lymphoblastic leukaemia (all). adult patients with philadelphia chromosome positive (ph+) relapsed or refractory b cell precursor all should have failed treatment with at least 1 tyrosine kinase inhibitor (tki).

Kanada - angol - Health Canada

amgen canada inc - darbepoetin alfa - solution - 15mcg - darbepoetin alfa 15mcg - hematopoietic agents